Interview with Aihua Pan, Chairman, SinoBioway Group
Could you provide us with an introduction to the company and an overview of operations from the company’s founding through to your position today as a leading biotech company in…
Address: PKU Biocity No. 39 ShangDiXi Lu, Haidian, Beijing, P.R. China
Tel: 86 10 8289 0924
SinoBioway Group Co., Ltd. was founded in 1992 and is one of the three major industry groups of Beijing University. It is mainly engaged in bio-industry development and the establishment of bio-economic systems with a focus on investment in three main areas: bio-medicine, bio-agriculture and bio-services. After more than ten years of dedication, the group has become China’s most influential and modern bio-enterprise.
The group now owns three main facilities: Beijing University Biological City, Beijing University Biological Park at Xiamen and Guangzhou Liuxi Biological Bay. Additionally, the group operates multiple holding subsidiaries such as Beijing Sinovac Biotech Co., Ltd., Xiamen Bioway-PKU Biotech Co., Ltd., Guangzhou Weiming Biotech Co., Ltd., Weiming Nature Unity Chinese Medicine Co., Ltd. and Beijing Weiming Kaituo Agricultural Biotech Ltd.
The main products of SinoBioway include an injection of mouse-nerve growth factor (Nobex ®), an inactivated hepatitis A vaccine (Healive ®), a hepatitis B vaccine (Bilive ®), anti-flu vaccines (Anflu ®, Panflu ®, and Panflu.1 ®), as well as hundreds of kinds of Chinese medicinal granules. The group now has established a fairly complete R & D system with centers for: Bio-Pharmaceutical Research, Vaccine Research, National Crop Molecular Design, Bio-Intelligence Research, Bio-Economic Research. It operates various institutions and R & D platforms while employing a group of outstanding research personnel.
Having researched mainly for the bio-economy, biological drugs (generic drugs and peptide drugs), human vaccines, modern Chinese medicine, molecular crop breeding, biomass energy and bio-intelligence technology, the group has achieved a series of major breakthroughs. These include the successful development and production of the world’s first drug treatment of traumatic nerve injury – the “nerve growth factor”, the world’s first “inactivated vaccine targeting SARS virus”, and China’s first “human-use influenza vaccine”. The world’s first influenza A (H1N1) vaccine -Panflu.1 ® was successfully produced on September 3, 2009. The group has initiated the world’s first “bio-economy incubator” (an efficient R & D system of new drugs), established a theoretical system of bio-economy, created an economic bio-restructuring model, and carried out a preliminary study of bio-industry development ideas suitable for China’s national conditions.
SinoBioway has engaged in corporate restructuring and through government guidance has shifted to a market approach. At the moment, the group has formed five industry groups on the basis of existing enterprises which include: vaccines, traditional Chinese medicine, bio-pharmaceuticals, modern agriculture and biological services. Through forming bio-economic systems in the industrial, R & D and financial arena, the group aims to build SinoBioway into a flagship company for the bio-economy era.
vaccines, traditional Chinese medicine, bio-pharmaceuticals
Could you provide us with an introduction to the company and an overview of operations from the company’s founding through to your position today as a leading biotech company in…
George Zhang, founder and chairman of Shenzhen-based ultrasound equipment developer and manufacturer, PRO, introduces his company’s groundbreaking high intensity focused ultrasound (HIFU) Noninvasive Therapy technology, and developing an innovative mindset…
As Professor of Neuroscience and Pain Medicine and director of the center for pain medicine at Southern University of Science and Technology (SUSTech) since 2016, Dr. Xue-jun Song explains the…
Shine Liu Xiancheng, CEO and founder of Lifotronic, discusses the rise of the medtech manufacturer over its ten years of existence, its commitment to R&D, and improving China’s innovation capacity.…
Zhang Guojian and Zhang Erying of in-vitro diagnostics manufacturer KingFocus Biomedical, introduce their company’s innovative ‘quantum dots’ technology, its development, client list, and the benefits of being based in Shenzhen.…
Dr. Grace Zhou, dean of SIIBR, discusses the Institute’s priorities, the benefits of being located in Shenzhen and the city’s potential as a global innovation hub. Zhou also outlines the…
Dr. Tang Dajie, founder and CEO of investment vehicle Triwise Capital, discusses the numerous investment opportunities in Shenzhen’s life sciences sector and the city’s unique geographical and economic positioning. Dr.…
Tian Yaolin, CEO of Shenzhen Govita Medical Laboratory, shares the exciting story of Govita’s start-up in the past two years; their robust and innovative business model centered on healthcare management…
Signed in June 2010, the Economic Cooperation Framework Agreement (ECFA) between Taiwan and China was set to reduce tariffs and commercial barriers between the two countries. Obviously, such a deal…
Many of your counterparts have spoken about the unique operational and strategic challenges China poses to their organizations. How does PAREXEL adapt itself to compete in China, and how does…
Every “sea turtle” has a different story. What’s yours, and how did you come to found Wincon? I am a “sea turtle” just like other Chinese returnees. I’m a medical doctor…
You are the CEO of GCP CMIC ClinPlus in addition to R&G PharmaStudies, and before that you headed a number of companies as well. Could you introduce yourself and all…
We’re meeting you just after a conference where you were a keynote speaker. Could you share with us some of your insights from the day’s events? The conference was a…
See our Cookie Privacy Policy Here
